Technology Transfer Revenues
Total Licensing Revenues
Total licensing revenues for OTT and campus offices rose 11% in FY96 to $70.3 million. Revenues include income from royalties, agreement issues and other fees, as well as expense reimbursements. This continues the steady upward trend reported over the past several years (Exhibit 10, below).
Royalties and Fee Income
The portion of licensing revenues from royalties and fees increased 10% in FY96 to $63.2 million. Exhibit 11 (below) indicates the income that OTT and the campus licensing offices contributed to this component of FY96 revenues.
Exhibit 10
TOTAL LICENSING REVENUES
(Millions)
Exhibit 11
Year Ended June 30, 1996
(Thousands)
| OTT | UCB | UCLA | UCSD | TOTAL | |
| Income from Royalties &Fees (-) Payments to Joint Holders Adjusted Gross Income* |
$61,546 (5,988) $55,558 |
$669 (36) $633 |
$944 (5) $939 |
$45 (0) $45 |
$63,204 (6,029) $57,175 |
*Adjusted gross income takes into account royalty income received by the University that is passed on to other institutions who are joint owners of income-generating patents - see section on Payments to Joint Holders
Four-hundred thirty-seven (437) inventions generated royalty and fee income in FY96. Income from the top five royalty-generating inventions contributed $46.2 million in FY96 (Exhibit 12, below), accounting for 73% of total income. The top twenty-five royalty-generating technologies collectively accounted for $56.0 million or 89% of total income. One utility invention, Phosphorus Plant Fertilizer, appeared on the list for the first time in FY96. The UC invention portfolio is considered to be especially strong because it has a large number of diverse inventions generating earned-royalty income at a high level, as well as new inventions moving into the top group each year.
Expense Reimbursements
In addition to income from royalties and fees, the University received $7.1 million in expense reimbursements from its licensees in FY96. Reimbursements typically cover legal costs associated with patenting an invention. Reimbursements are a high priority objective during the license negotiation. Such reimbursements are considered to be part of the total licensing revenues, although they are treated as an offset to legal and other direct expenses for financial reporting purposes (see section on Legal Expenses).
Exhibit 12
UC TOP EARNING
COMMERCIALIZED INVENTIONS*
(Thousands)
| (Invention, Campus, Year Disclosed) FY96 Hepatitis-B Vaccine (SF, 1979 and 1981) Process for Splicing Genes (SF, 1974) Human Growth Hormone (SF, 1977) Nicotine Patch (LA, 1984) Radiographic Media (SD, 1979) Subtotal (Top Five Inventions) Treatment-Intercranial Aneurysms (LA, 1989) |
1,196 |